Advances in endocrine and targeted therapy for hormone-receptorpositive, human epidermal growth factor receptor 2-negative advanced breast cancer

二维码有效期 120s

摘要Nearly 70% of breast cancer (BC) is hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and endocrine therapy is the mainstay of treatment for this subtype. However, intrinsic or acquired endocrine resistance can occur during the endocrine treatment. Based on insights of endocrine resistance mechanisms, a number of targeted therapies have been and continue to be developed. With regard to HR-positive, HER2-negative advanced BC, aromatase inhibitor (AI) is superior to tamoxifen, and fulvestrant is a better option for patients previously exposed to endocrine therapy. Targeted drugs, such as cyclindependent kinases (CDK) 4/6 inhibitors, mammalian target of rapamycin (mTOR) inhibitors, phosphoinositide-3-kinase (PI3K) inhibitors, and histone deacetylase (HDAC) inhibitors, play a significant role in the present and show a promising future. With the application of CDK4/6 inhibitors becoming common, mechanisms of acquired resistance to them should also be taken into consideration.

abstractsNearly 70% of breast cancer (BC) is hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and endocrine therapy is the mainstay of treatment for this subtype. However, intrinsic or acquired endocrine resistance can occur during the endocrine treatment. Based on insights of endocrine resistance mechanisms, a number of targeted therapies have been and continue to be developed. With regard to HR-positive, HER2-negative advanced BC, aromatase inhibitor (AI) is superior to tamoxifen, and fulvestrant is a better option for patients previously exposed to endocrine therapy. Targeted drugs, such as cyclindependent kinases (CDK) 4/6 inhibitors, mammalian target of rapamycin (mTOR) inhibitors, phosphoinositide-3-kinase (PI3K) inhibitors, and histone deacetylase (HDAC) inhibitors, play a significant role in the present and show a promising future. With the application of CDK4/6 inhibitors becoming common, mechanisms of acquired resistance to them should also be taken into consideration.

作者 Shen Le-Sang ^[1] Jin Xiao-Yan ^[2] Wang Xu-Meng ^[3] Tou Lai-Zhen ^[3] Huang Jian ^[1] 学术成果认领

作者单位 Department of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China; Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, Zhejiang 310009, China ^[1] Department of Surgical Oncology, Zhejiang Taizhou Municipal Hospital, Taizhou, Zhejiang 318000, China ^[2] Department of Surgical Oncology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China ^[3]

关键词 Endocrine therapy Advanced breast cancer Endocrine resistance Targeted therapy Endocrine therapy Advanced breast cancer Endocrine resistance Targeted therapy

主题词人类(Humans)受体, 表皮生长因子(Receptor, Epidermal Growth Factor)乳腺肿瘤(Breast Neoplasms)乳房(Breast)治疗学(Therapeutics)

栏目名称 Review Article

DOI 10.1097/CM9.0000000000000745

发布时间 2025-02-25